A Registry Study of Participants With Multiple Myeloma in Latin America (MYLACRE)

Janssen (J&J Innovative Medicine)

Status: Completed

Conditions: Multiple Myeloma

Treatments: Other: No intervention

Study type: Observational

Funder types: Industry

Identifiers

NCT03955900

CR108622

54767414MMY4021 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to characterize the multiple myeloma (MM) population concerning demographics and clinical characteristics (for example. frailty, risk strata, manifestations of target organ damage [TOD]) in 6 countries (that is Argentina, Brazil, Mexico, Chile, Colombia and Panama); and to profile the treatment landscape of Latin American MM participants, including factors associated with health-care provider (HCP) selections of different treatment regimens. These factors can include a participant's demographic and clinical characteristics and availability of different therapy options per institution in each country.

Enrollment: 2,059 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Incident diagnosis of MM between 01 January 2016 and 31 December 2020 (that is the first observed diagnosis noted in the medical charts)
• An informed-consent form (ICF) or participation agreement must be signed before any data are collected only if a waiver is not permissible. For deceased participants who did not provide consent before death, the permission to research on their information should satisfy the local requirements (that each study site's ethics committee and each country's regulatory authority)

Exclusion criteria

• Failed to satisfy one or more of the foregoing inclusion criteria or
• Only with diagnosis of smouldering myeloma between 01 January 2016 and 31 December 2020 in the medical charts

Trial design

2,059 participants in 1 patient group

Participants with Multiple Myeloma (MM)

Description:

Participants with MM will be observed in real-world clinical practice settings. The primary data source for this study will be the medical records of each participant.

Treatment:

Other: No intervention